Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 9, 2015, Pages 11537-11542

  Huang, Huan ^a   Liu, Jihong ^a   Meng, Qinglian ^a   Niu, Guozhong ^a  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Brain metastasis; Multidrug resistance protein; Non small cell lung cancer; Topoisomerase 2 alpha

Indexed keywords

DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; TUMOR ANTIGEN;

ADULT; AGED; BRAIN TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY;

ADULT; AGED; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RETROSPECTIVE STUDIES;

EID: 85013324824     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. Sakamoto J, Sonobe M, Kobayashi M, Ishikawa M, Kikuchi R, Nakajima D, Yamada T, Nakayama E, Takahashi T, Sato T, Chen F, Bando T and Date H. Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer. Int J Clin Oncol 2014; 19: 50-56.
3. Melloni G, Bandiera A, Gregorc V, Carretta A, Ciriaco P, Vigano M, Franzin A, Bolognesi A, Picozzi P and Zannini P. Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience. J Cardiovasc Surg 2011; 52: 613-619.
4. Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF and Pairolero PC. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 2001; 122: 548-553.
5. Schouten LJ, Rutten J, Huveneers HA and Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94: 2698-2705.
6. Smedby KE, Brandt L, Backlund ML and Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 2009; 101: 1919-1924.
7. Wang J, Zhang J, Zhang L, Zhao L, Fan S, Yang Z, Gao F, Kong Y, Xiao GG and Wang Q. Expression of P-gp, MRP, LRP, GST-pi and TopoIIalpha and intrinsic resistance in human lung cancer cell lines. Oncol Rep 2011; 26: 1081-1089.
8. Yan S, Shun-Chang J, Li C, Jie L, Ya-Li L and Ling-Xiong W. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. BMC Cancer 2010; 10: 621.
9. Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, Cantonati H, Attems J, Gsur A and Micksche M. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005; 131: 355-363.
10. Chen ZJ, Le HB, Zhang YK, Qian LY, Sekhar KR and Li WD. Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance. J Int Med Res 2011; 39: 1693-1700.
11. Xu Y, Wang L, Zheng X, Liu G, Wang Y, Lai X and Li J. Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients. Mol Clin Oncol 2013; 1: 487-492.
12. Chen W, Qiu J and Shen YM. Topoisomerase IIalpha, rather than IIbeta, is a promising target in development of anti-cancer drugs. Drug Discov Ther 2012; 6: 230-237.
13. Dingemans AC, van Ark-Otte J, Span S, Scagliotti GV, van der Valk P, Postmus PE and Giaccone G. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 2001; 32: 117-128.
14. Won YW, Joo J, Yun T, Lee GK, Han JY, Kim HT, Lee JS, Kim MS, Lee JM, Lee HS, Zo JI and Kim S. A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. Lung Cancer 2015; 88: 201-207.
15. Liao Y, Yang F, Li X, Chen K, Zhou L, Wang Y and Wang J. The impact of Caspase-8 on non-small cell lung cancer brain metastasis in II/III stage patient. Neoplasma 2015; [Epub ahead of print].
16. Xie SS, Tan M, Lin HY, Xu L, Shen CX, Yuan Q, Song XL and Wang CH. Overexpression of adenylate cyclase-associated protein 1 may predict brain metastasis in non-small cell lung cancer. Oncol Rep 2015; 33: 363-371.
17. Alsan Cetin I, Akgun Z, Atasoy BM, Fulden Yumuk P and Abacioglu U. Who may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients? J BUON2013; 18: 453-458.
18. Ji Z, Bi N, Wang J, Hui Z, Xiao Z, Feng Q, Zhou Z, Chen D, Lv J, Liang J, Fan C, Liu L and Wang L. Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol Biol Phys 2014; 89: 330-337.
19. Su W and Pasternak GW. The role of multidrug resistance-associated protein in the blood-brain barrier and opioid analgesia. Synapse 2013; 67: 609-619.